Evidence map›Paper›PMID 25516852›Full record

ReviewWorld journal of clinical cases2014

New targeted therapies for breast cancer: A focus on tumor microenvironmental signals and chemoresistant breast cancers.

Armel Hervé Nwabo Kamdje, Paul Faustin Seke Etet, Lorella Vecchio, Richard Simo Tagne, Jeremie Mbo Amvene, Jean-Marc Muller, Mauro Krampera, Kiven Erique Lukong

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of clinical cases, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. The Role of Smoothened in Cancer.International journal of molecular sciences · 2020
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Armel Hervé Nwabo KamdjeArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Paul Faustin Seke EtetArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Lorella VecchioArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Richard Simo TagneArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Jeremie Mbo AmveneArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Jean-Marc MullerArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Mauro KramperaArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
Kiven Erique LukongArmel Hervé Nwabo Kamdje, Richard Simo Tagne, Jeremie Mbo Amvene, Department of Biomedical Sciences, Faculty of Sciences, University of Ngaoundéré, PO Box 454, Ngaoundéré, Cameroon.
University of Ngaoundéré · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the most frequent female malignancy worldwide. Current strategies in breast cancer therapy, including classical chemotherapy, hormone therapy, and targeted therapies, are usually associated with chemoresistance and serious adverse effects. Advances in our understanding of changes affecting the interactome in advanced and chemoresistant breast tumors have provided novel therapeutic targets, including, cyclin dependent kinases, mammalian target of rapamycin, Notch, Wnt and Shh. Inhibitors of these molecules recently entered clinical trials in mono- and combination therapy in metastatic and chemo-resistant breast cancers. Anticancer epigenetic drugs, mainly histone deacetylase inhibitors and DNA methyltransferase inhibitors, also entered clinical trials. Because of the complexity and heterogeneity of breast cancer, the future in therapy lies in the application of individualized tailored regimens. Emerging therapeutic targets and the implications for personalized-based therapy development in breast cancer are herein discussed.

Indexed as

Breast cancerChemoresistanceMicroenvironmentSignaling moleculeTargeted therapy

Identifiers

PMID25516852
PMCPMC4266825
OpenAlexW43703026

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.